Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Active not recruiting 2Suspended 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 278Carcinoma, Non-Small-Cell Lung 228Prostatic Neoplasms 183Neoplasms 180Multiple Myeloma 140Lung Neoplasms 137Neoplasm Metastasis 104Colorectal Neoplasms 101Melanoma 87Ovarian Neoplasms 86Leukemia, Myeloid, Acute 78Pancreatic Neoplasms 73Lymphoma 72Leukemia, Lymphocytic, Chronic, B-Cell 67Carcinoma, Renal Cell 65Squamous Cell Carcinoma of Head and Neck 64Lymphoma, Non-Hodgkin 64Brain Neoplasms 64Recurrence 57Urinary Bladder Neoplasms 56Carcinoma, Hepatocellular 56Hematologic Neoplasms 55Head and Neck Neoplasms 55Triple Negative Breast Neoplasms 52Lymphoma, Follicular 49Glioblastoma 49Endometrial Neoplasms 48Uterine Cervical Neoplasms 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Sarcoma 44

Interventions

Solutions 1Everolimus 1Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Seizures × 90 days × Clear all
NCT05485831 2026-06-03

EpiTALY

Jazz Pharmaceuticals

Active not recruiting
111 enrolled

Epilepsies, Myoclonic, Seizures, Tuberous Sclerosis, Lennox Gastaut Syndrome

NCT02962414 2026-04-02

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Novartis

Phase 3 Active not recruiting
206 enrolled

Seizures, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡